Assessment of puberty in relation to L-carnitine and hormonal replacement therapy in β-thalassemic patients

Journal of Tropical Pediatrics

Volumn 54, Issue 6, 2008, Pages 375-381

  El Beshlawy, Amal ^a   Mohtar, Galila ^a   Abd El Ghafar, Esmat ^b   Abd El Dayem, Soha M ^a,b   El Sayed, Manal Hamdy ^a   Aly, Azza Ahmed ^b   Farok, Manal ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

thalassemic; Hormonal therapy; L carnitine; Puberty

Indexed keywords

CARNITINE; CHORIONIC GONADOTROPIN; CONJUGATED ESTROGEN; DEFEROXAMINE; ESTRADIOL; FOLIC ACID; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; SEX HORMONE; TESTOSTERONE PROPIONATE;

ADOLESCENT; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATIONAL STUDY; DELAYED PUBERTY; DRUG EFFICACY; FEMALE; FOLLOW UP; GONAD DYSFUNCTION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; LABORATORY TEST; LIVER DYSFUNCTION; MALE; MENSTRUATION; OUTCOME ASSESSMENT; PRIMARY AMENORRHEA; SECONDARY AMENORRHEA; TREATMENT DURATION;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CARNITINE; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; PREVALENCE; PROGESTERONE; PUBERTY, DELAYED; TESTOSTERONE;

EID: 57649165845     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmn043     Document Type: Article

References (26)

1. Raiola G, Golati MC, De Sanctis V, et al. Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab 2003;(suppl 2): 259-66.
2. Mohammadian S, Bazrafshan HR. Sadeghi-Nejad Ab. Endocrine gland abnormalities in thalassemia major: A brief review. J Pediatr Endocrinol Metabol 2003; 16:957-64.
3. Rund D, Rachmilewitz EA. Beta-thalassemia. N Engl J Med 2005;353:1135.
4. Abdelrazik N, Ghanem H. Failure of puberty in Egyptian Beta-thalassemic patients: Experience in north east region-Dakahlia province. Hematology 2007;1.
5. Aessopos A, Farmakis D, Deftereos S, Papalambros E. Cardiovascular effects of splenomegaly and splenectomy in Beta-thalassemia. Ann Hematol 2005;84:353.
6. Moayeri H, Oloomi Z. Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in Beta- thalassemia major. Arch Iran Med 2006;9:329-34.
7. Aydinok Y, Darcan S, Polat A, et al. Endocrine complications in patients with B - thalassemia major. J Trop Pediatr 2003;48:50-4.
8. El Beshlawy A, Abdel Dayem S, Abd El Raouf E, et al. Effect of L-carnitine on growth of Egyptian children with thalassemia major. Med J Cairo Univ 2001;69:7-12.
9. Genazzani AD, Petraglia F, Algeri I, et al. Acetyl-L-carinitine as possible drug in the treatment of hypothalamic amenorrhea. Acta Obstet Gynecol Scand 1992;70:487-92.
10. Tanner JM, Whitehouse RH. A note on the bone age at which patients with true isolated GH deficiency enter puberty. J Clin Endocrinol Metab 1976;41:788.
11. Zachman M, Prader A, Kind HP, et al. Testicular volume during adolescence: Cross-setional and longitudinal studies. Helv Paediatr Acta 1987;29:61-72.
12. Italian Working Group on Endocrine Complications in Non-Endocrine Diseases. Multicentre study on prevalence of endocrine complications in thalassemia major. Clin Endocrinal 1995;42:581-6.
13. Blythe MI. Common menstrual problems of adolescence. Adolesc Med State Art Rev 1997;8:87.
14. Anapliotou MLG, Kastania IT, Psara P, et al. The contribution of hypogonadism to the development of osteoporosis in thalassemia major: new therapeutic approaches. Clin Endocrinol 1995;42:279-87.
15. Goodpasture JC, Ghai K, Cara JF, Rosenfield RL. Potential of gonadotropin-releasing hormone agonists in the diagnosis of pubertal disorders in girls. Clin Obstet Gynecol 1993;36:773.
16. Soliman AT, El Zalabany M, Amer M, Ansari BM. Growth and pubertal development in transfusion dependant children and adolescents with thalassemia major and sickle cell disease: A comparative study. J Trop Pediatr 1999;45:23-30.
17. Valenti S, Guiti M, McGuiness D, Guido R. Delayed puberty in males with beta-thalassaemia major: Pulsatile gondadotrophin isoform profiles and an increase in sex steroid. Eur J Endocrinol 1995;13:48-56.
18. Pantelakis S. Thyroid disorder and diabetes mellitus as a complication of thalassemia major. Acta Pediatr Suppl 1994;406:111-3.
19. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, et al. Effect of age at the start of iron chelation therapy on gonadal function in B-thalassemia major. New Engl J Med 1990;323:713-9.
20. Borgna-Pignatti C, Zurlo MG, De Stefano P, et al. Outcome of thalassemia treated with conventional therapy. Bone Marrow Transpl 1993; 12(suppl 1):2-4.
21. Grundy RG, Woods KA, Savage MO, Evans JPM. Relationship of endocrinopathy to iron chelation status in young patients with thalassemia major. Arch Dis Child 1994;71:128-32.
22. Oerter KE, Kamp GA, Munson PL, et al. Multiple hormone deficiencies in children with hemochromatosis. J Clin Endocrinol Metab 1993;76:357-61.
23. Aydmok Y, Darcan S, Polat A, et al. Endocrine complications in patients with beta-thalassemia. J Trop Pediatr 2002;48:50-4.
24. Landau H, Matoth I, Landau-Cordova Z, et al. Cross sectional and longitudinal study of pituitary-thyroid axis in patients with thalassemia major. Clin Endocrinol 1993;38:55-61.
25. Arduini A, Dottori S, Molajoni F, et al. Is the carnitine system part of the heart antioxidant network. In: DeJong JW, Ferrari R (eds). The carnitine system. A new therapeutic approach to cardiovascular diseases. Dordrecht: Kluwer Academic Publishers, 1995;169-81.
26. Miller-Bassk, Adashi E. Current status and future prospects for transdermal estrogen replacement therapy. Fertil Steril 1990;53:961-74.